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The following equity research on Canopy Growth Corporation, a cannabis and hemp producer, 
will provide an overview of the current state of the company, focusing on its strategy, sales and 
products, as well as an overview of the sector. Subsequently, there will be an analysis of the 
company’s financial position followed by a detailed forecasting of its financial statements in 
order to obtain the enterprise value of Canopy Growth. At last, given an estimated share price 
of C$ 29.02, compared to the current share price of C$ 27.31, a hold recommendation is 
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▪ We start the analysis of Canopy Growth Corporation with a 
recommendation to hold the WEED stock given our FY20 target 
price of C$29.02, compared to the current price of C$27.31. The 
difference in prices corresponds to an upside of, approximately, 
6.3%. This leads us to believe that it is preferable to hold the stock 
as it might yield higher returns in the future. 
▪ Canopy Growth is currently the biggest company by market 
capitalization in the cannabis industry (C$9.5B), with an 
expected CAGR of 30-35% mainly driven by the forthcoming 
legalization for recreational use internationally, and the prospects 
of the new high margin cannabis 2.0 segment. 
▪ The company is investing in the Cannabis 2.0 segment, recently 
legalized in Canada (October 2019), an opportunity supported by 
the investment of C$5B from Constellation Brands, which provided 
expertise in operations, product distribution and marketing. 
▪ We model the target share price using a DCF valuation, 
discounting FCF at a WACC level of 6.05% and a perpetuity 
growth rate of 3.6%. 
Company description 
Canopy Growth Corporation (TSX:WEED, NYSE:CGC) is a 
Canadian based company, that dedicates to the production, 
distribution and sale of cannabis for medical and recreational 
purposes. The company was founded in 2013 by Bruce Linton and 
Chuck Rifici, formerly under the name Tweed Marijuana Inc., and 
renamed Canopy Growth Corporation in 2015. 
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With Dope there’s hope 
Hold on!... to Canopy’s Growth stock 
Recommendation: HOLD 
Vs Previous Recommendation HOLD 
Price Target FY20: C$ 29.02 
Vs Previous Price Target C$ 28.58 
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Bloomberg; Company data; Analysts estimates 
  
52-week range (C$) 18.23-70.98 
Market Cap (C$ b) 9.5 
Outstanding Shares (m) 348.33 
  














2019 2020E 2021F 
Revenues 226 341 486 564 625 670 
EBITDA - 519 929 - 697 756 - 928 880 
Net Loss - 683 858 - 661 072 - 836 474 
EPS (in C$) - 2.51 - 2.48 - 2.34 
P/E -11.6x -11.7x -12.4x 
Sales growth (%) 190% 115% 29% 
Source: Company Data; Analysts Estimates; Bloomberg 
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Canopy Growth Corporation (“Canopy Growth”, “Canopy” or the “Company”) is a 
world-leading diversified cannabis and hemp company, with operations in 15 
countries across 5 continents and headquartered in Smith Falls, Canada. The 
Company was founded in 2013 by Bruce Linton and Chuck Rifici, formerly under 
the name Tweed Marijuana Inc., and renamed Canopy Growth in 2015. The main 
activities are the production, distribution, and sale of cannabis for global medical 
and the Canadian recreational use markets.  
During 2019, Linton, Canopy Growth’s CEO, was fired. December of the same 
year, Canopy appointed Constellation Brands CFO and Canopy’s executive, 
David Klein, has the new chief executive officer.  
Canopy Growth became the first licensed cannabis producer in Canada to go 
public in 2014, and is currently traded on the Toronto Stock Exchange (“TSX”), 
listed under the symbol “WEED”. In 2018 became the first cannabis company to 
be listed on the NYSE, under the trading symbol “CGC”. Canopy Growth is 
currently the largest marijuana stock in the world by market capitalization (C$9.5 
billion). 
Through its wholly‑owned subsidiaries, Canopy Growth operates numerous state-
of-the-art production facilities with over 4.8 million square feet of indoor and 
greenhouse production capacity. Net revenue in fiscal 2019 was C$226.3 million 
(C$140.5 million of gross revenue from new Canadian recreational channel and 
C$78.9 million in global medical sales), as compared to $77,948 in fiscal 2018. 
The year-over-year increase is attributable to the launch of the Canadian 
recreational cannabis market in October 2018. In 2019 the company reported that 
it employed over 3000 workers.  
 
Product & Sales Analysis 
Canopy Growth offers distinct brands and curated cannabis varieties in dried 
flower, oils, concentrates and soft gel capsule forms. In October 2019, with the 
legalization of Cannabis 2.0, Canopy added to its product portfolio edibles, 
beverages and vapes. 
 
Exhibit 2: 2019 Revenue by segment 
Exhibit 1: International subsidiaries, 












Dried flower is the core product of the company representing more than half of 
total revenues (53%) in 2019. This corresponds to C$134 million, from which 
C$82 million came from the recreational segment and C$51 million from medical. 
Although there was a decrease of dry bud medical sales in comparison to 2018 
(C$51 million vs C$58 million), the overall revenue of this product type registered 
128% increase, driven by the legalization of the recreational use in October 2018. 
The cannibalization observed, from medical sales to recreational, can be 
explained by the price difference between the two segments. While recreational 
cannabis registered an average price of C$8.65 per gram (only sold in Canada), 
medical cannabis registered C$9.39 in Canada and C$13.53 Internationally.  
Canopy Growth also produces cannabis extracts that use supercritical fluid CO2 
extraction technology to obtain Oils and Concentrates. This process extracts the 
major cannabinoids (THC and CBD), as well as the minor cannabinoids, 
terpenes, and flavonoids that contribute to the overall medicinal value of medical 
cannabis, resulting in a highly concentrated resin that can be dissolved in a food 
oil carrier to comply with government regulations and to make it easier to 
administer orally.   
In 2016, Canopy introduced Softgel Capsules as a way of consuming the 
product in a pill form. These capsules are filled with extract cannabis resin, 
available in a variety of medicinal concentrations (micro/full doses), providing an 
accurate dosing. This form has several advantages such as being discreet, 
portable and relief from smoking.  
Compared to dried flower, oils and softgel capsules yield much higher margins. 
Jointly, they accounted for 34% of the revenue in 2019, generating C$85 million, 
from which $57 million came from the recreational segment and C$27 million from 
medical.  
Nonetheless, Canopy Growth noted an oversupply of oils and softgels in certain 
Canadian provinces. Retailers were not selling these products, resulting in a glut 
of inventory due, in part, to underdeveloped retail markets in several provinces. 
Based on this assessment, Canopy determined returns and pricing adjustments 
in the amount of C$32,727 and have reduced the production of certain 
recreational cannabis oil and softgel products. 
The remaining 13% of the revenues came from other products, reaching sales of 
C$34 million, as compared to C$3.5 million in 2018. The year-over-year increase 
is attributable to sales of Storz & Bickel vaporizer devices, along with revenue 
from other strategic sources including extraction services and clinic partners. 
Exhibit 3: Canadian and International 
Medical Revenues 
 
Exhibit 4: Canopy Price (per gram) Canadian 
and International Medical Cannabis 
 












Canopy will produce cannabis-infused beverages in the new 160,000 square foot 
beverage facility in Smiths Falls. The Company developed a proprietary process 
that distils whole flower cannabis into a clear liquid that will be used as an active 
ingredient in beverages. 
Canopy also has a partnership with Bean & Bud to produce a line of premium 
cannabis-infused craft chocolates with 5 milligrams of THC per serving. 
 
Strategy Analysis 
Canopy Growth has been pursuing a strategy to position itself as the dominant, 
global leader in cannabis and hemp-based products. At the expense of an 
aggravation of its financial losses in the short term, the company has been 
committed to an expansion strategy that sacrifices profits to invest heavily in 
growth.  
With the liquidity provided by Constellation Brands cash injection of C$5 billion in 
October 2018, Canopy was able to follow a strategy that prioritizes on innovation 
and product development, production capacity and capability, and global 
expansion through mergers and acquisitions. 
However, Canopy Growth failed to hit revenue and profitability targets in 2019. 
There were external factors influencing this scenario, namely lower store rollouts 
and rising black market sales, related to the slow pace at which Health Canada is 
processing the requirements for licenses and the higher prices that legal cannabis 
have over illegal sources. There were also internal factors that aggravated this 
scenario, like the miscalculations that led to an oversupply of oils and softgels. 
Hence, investors manifested concerns with the capability of Canopy to generate 
returns.  
Nonetheless, we believe that these investments were necessary to gain 
competitive advantages mainly through synergies, elimination of competition and 
innovation, therefore increasing market share and fulfill Canopy’s goal. 
Also influencing Canopy’s strategy is the recent nomination of David Klein as the 
new CEO. Upon the announcement of the new leadership, the stock shot up by 
14 percent, indicating a high confidence in Klein’s leadership abilities before he 
had even assumed the post.  
We believe that Klein will bring some stability to the Company and that he will be 
able to consolidate what was done in the previous years: he already has 
experience working with Canopy since he was pointed chairman of the company 
in October 2019, giving him ample time to make inquiries and become prepared 
The company has been 
committed to an 
expansion strategy that 
sacrifices profits to 
invest heavily in growth 
 
 








for making executive decisions. Additionally, when David Klein was 
Constellation’s CFO, his skills and contributions to the betterment of the company 
were officially recognized as he was awarded the title of “best CFO” by 
Institutional Investor magazine three years consecutively1, further proving his 
solid reputation as a successful leader. 
 
▪ Innovation and Product Development (R&D) 
Research and development expense in fiscal 2019 was C$15.2 million, as 
compared to C$1.5 million in fiscal year 2018. The year-over year increment of 
C$13.8 million is attributable to increased compensation costs due to an addition 
of the number of employees conducting research into several intellectual property 
opportunities, and other strategic investments including developing patent-
pending technology in the following areas: 
- New cannabis-based product form factors that will enter the market when 
permitted (expect to be in late 2019); 
- Device and delivery technology, including vaporizers; 
- Growth patterns under different environmental scenarios and the genetics of 
various strains; 
- Production of encapsulated cannabis oil capsules in higher volumes; and 
- Equipment engineered specifically for the cannabis industry, such as 
extraction equipment. 
By comparison, Aurora Cannabis R&D expense in 2019 was very similar to 
Canopy, around C$14.7 million, while Aphria only registered  $1,391. 
Canopy is also conducting clinical trials for CBD-based human and animal health 
products. Through Spectrum Therapeutics’ research and development initiatives, 
Canopy continues to build a portfolio of intellectual property, with 130 patents 
issued up to date. 
Canopy Growth also acquired a portfolio of hemp-specific intellectual property 
when it acquired Colorado-based Ebbu Inc., in November 2018. With more than 
40 cannabis-related patents filed representing over 1500 inventions, Ebbu 
science team has become a global leader in data-driven and lab-tested 
cannabinoid research. 
 
1 Allen lee. 2019. “20 things you didn’t know about David Klein”. https://moneyinc.com/david-klein/ 
 












▪ Production Capability and Capacity  
For Canopy, Canada continues to represent the majority of the revenue, with its 
federally-regulated recreational and medical markets, with approximately 4,8 
million square feet of licensed capacity for greenhouse and indoor cultivation, 
post-harvest processing, oil extraction, encapsulation, advanced manufacturing 
for pre-rolled joints and chocolates, vape manufacturing and beverage production 
capability.  
In 2019, Canopy harvested 46,927 kilograms of cannabis, as compared to 22,513 
kilograms in 2018. The increase is attributable to the build-out of production 
capability over the last fiscal year in preparation for the launch of the Canadian 
recreational market. 
Accordingly, 24,320 kilograms and kilogram equivalents of cannabis were sold 
during 2019, up from 8,708 kilograms and kilogram equivalents in fiscal 2018. 
The increase was due to the launch of the Canadian recreational market on 
October 2018, that accounted for 67% of total cannabis sold (Medical 33%), of 
which 84% was sold directly to the Canadian provinces and the remainder 
through direct retail and on-line consumer channels.  
Canopy used to be the leader in terms of production capacity in relation to its 
peers. However, Aurora Cannabis has ramped up its production capabilities over 
the past year, producing now 57,442 kilograms of cannabis and selling 36,628 
kilograms. 
Currently Canopy has 27 cannabis retail stores operating under the Tweed or 
Tokyo Smoke banner, and an e-commerce platform. Canopy has also received 
licences, rights to licences or permits to apply for licences to operate cannabis 
retail stores in 4 provinces:  
- Newfoundland & Labrador - licences for up to 7 stores;  
- Manitoba - licences for up to 15 stores;  
- Saskatchewan - licences for up to 6 stores; and  
- Alberta – development permits for over 20 store locations.  
 
In Ontario, Canopy has entered into multi-year licensing agreements to enable its 
partners to open one Tokyo Smoke branded and one Tweed-branded cannabis 
store.  
▪ Global Expansion and M&A Activity  
M&A activity in the cannabis industry is characterized for being fierce. Companies 
want to gain as much market share as they can in this early stage while there is a 












lot of space to grow. Therefore, and in accordance with industry “standards”, 
Canopy Growth has been under an intense acquisition activity that aims to 
accelerate the global expansion strategy, including entering the United States 
market when federally permissible to do so; investing in the recently-legalized 
hemp market in the United States; building-out infrastructure in new markets; 
investing in intellectual property development and advancing clinical research 
programs. 
Hence, aiming to accelerate the pathway into the United States cannabis market, 
in April 2019, Canopy Growth entered into an agreement with Acreage Holdings, 
Inc. (“Acreage”), a leading multi-state cannabis operator in United States, that 
owns or has managed services agreements in place for cannabis-related licenses 
across 20 U.S. states, including 87 dispensaries and 22 cultivation and 
processing facilities. With this agreement, Canopy Growth has the right, to 
acquire 100% of the shares of Acreage, with the requirement to do so at such 
time as cannabis production and sale becomes federally-permissible in the 
United States. 
Upon completion of the deal, Acreage shareholders will receive an immediate 
payment of US$300 million and, upon Canopy Growth’s exercise of the Right, 
Acreage shareholders will receive 0.5818 of a common share of Canopy for every 
Acreage share held, subject to adjustment in accordance with the plan of 
arrangement. This represented total consideration of approximately US$3.4 billion 
at April 16, 2019, which reflects a 41.7% premium over the 30-day volume-
weighted average price of Acreage Holdings shares. 
The odds appear to be in favor of the deal to happen since in November 2019, for 
the first time in American history, a congressional committee approved a 
marijuana legalization bill.  
Nonetheless, this deal also carries some risks that should not be neglected as the 
fact that there will be a massive dilution to Canopy Growth's shareholders2. 
It is also part of Canopy Growth expansion strategy to further grow operations in 
the European market. Therefore, in March 2019, the company completed the all-
cash acquisition of Spain-based licensed cannabis producer Cáñamo y Fibras 
Naturales, S.L. (“Cafina”), one of three companies in Spain authorized to 
cultivate, distribute and export cannabis containing more than 0.2% of THC for 
medicinal and research purposes. Cafina is also licensed to cultivate hemp. This 
acquisition aims to expand the European production footprint and improve the 
 












long-term positioning to address demand across Europe for medical cannabis 
and CBD products. 
In May 2019, Canopy Growth acquired Germany-based C3 Cannabinoid 
Compound Company (“C3”), Europe’s largest cannabinoid-based 
pharmaceuticals company, in a C$343 million deal, furthering Canopy Growth’s 
expansion into European markets with prescription medicines. C3 has a total of 
five medicines in the market and in 2018 supplied approximately 19,500 patients 
in Germany, a year-over-year increase of 85%, achieving worldwide sales of 
C$41.5 million. 
In the same month, Canopy Growth invested C$55 million to acquire London, 
England-based This Works, a global leader in natural skincare and sleep 
solutions with a customer base spanning 35 countries. 
More recently, Canopy Growth decided to invest in the sports nutrition market, 
currently estimated at being worth $50 billion worldwide3, by acquiring 72% of 
North American-based, BioSteel Sports Nutrition. Initial cash consideration was 
$50,535 and the purchase price will be subject to a further adjustment based on a 
multiple of BioSteel’s 2019 net revenue. This acquisition allows Canopy Growth to 
enter the sports nutrition space with a strong and growing brand, that has more 
than 10,000 points of distribution in Canada and the US, allowing Canopy Growth 
to scale out its own CBD beverage products in the future with this established 
retail chain. BioSteel has a strong sports nutrition consumer base in the North 
American market and Canopy Growth views the adoption of CBD in future 
BioSteel offerings as a potentially significant and disruptive growth driver for the 
business given the negative effects of prescription painkillers and that athletes 
are looking for healthier alternatives4. BioSteel’s products have been used by 
70% of North America's major sports leagues, including the NFL, NHL, MLB. The 
challenge, however, will be in convincing different leagues to allow CBD to be 
used as a treatment option. Although there's interest from players in using CBD, 
there is no guarantee that the substance will be permitted. 
Furthermore, just like with many cannabis products, the competition in this 
segment is intense. Canopy rival, Aurora Cannabis partnered with UFC to 
research the use of hemp-derived CBD as an effective treatment for pain, 
inflammation, wound-healing, and recovery on mixed-martial-art athletes. Unlike 
Canopy, however, the deal does not extend any further to potential retail 
partnerships, so in this sense, Canopy does hold an edge over its rival. Tilray, 
 
3 M.Shahbandeh.2019. “Global sports nutrition market”. https://www.statista.com/statistics/450168/global-sports-nutrition-market/ 












another Canadian cannabis producer, has an agreement to provide CBD 
ingredients for wellness products backed by former professional golfer Greg 
Norman. 
Canopy Growth presented a loss of C$1.4 billion and a deeper analysis reveals 
that C$826 million of it was due to M&A activity5. While Canopy has significant 
cash reserves, the rate at which it is allocating funds on acquisitions might lead to 
a scarcity of capital within the next quarters if management doesn't slow down. 
 
Goodwill 
The intense M&A activity entails consequences that affect all major players. With 
increased competition to gain market share, cannabis companies have been 
overpaying for acquisitions and goodwill has exponentially increased6. Players in 
the cannabis industry are conquering the market by acquiring smaller players, 
even if it requires the payment of sizable amounts of cash. The fundamental idea 
for this M&A activity is to: increase production capacity faster (buying already 
established greenhouses and cultivation fields instead of building themselves) 
and absorb companies that have already invested in R&D and have valuable 
intellectual property, preferably companies that already have licenses to produce 
in other countries. In the end, the goodwill ends up with high values, which leads 
us to believe the company might be overpaying for smaller ones it is absorbing. 
Canopy Growth's registered an increase of almost 400% in goodwill, from C$314 
million in 2018 to C$1.5 billion in 2019. Constellation C$5 billion cash injection in 
2018 allowed Canopy to more than double the number of companies acquired 
during the following months. 
Leading the ranking of premiums paid in acquisitions is Aurora Cannabis with a 
goodwill of C$3.2 billion, which account for 57% of total assets and is now larger 
than the company's market cap of C$2.38 billion on the NYSE7. Aurora claimed at 
least half, if not close to 80%, of the value of the deals it made in the last three 
year as goodwill, including the C$2.64 billion acquisition of MedReleaf, of 
which C$2 billion was declared as goodwill. 
With relatively lower goodwill on their balance sheets, Aphria registers C$669 
million, much of which is tied to its 2018 purchase of Nuuvera, and Tilray with 
C$155 million in goodwill from the purchase of Manitoba Harvest.  
 
5 Mark Prvulovic.2019. “How Big a Deal Is Canopy Growth's Recent Sports Beverage Acquisition?”. https://www.fool.com/investing/2019/10/08/how-big-a-
deal-is-canopy-growths-recent-sports-bev.aspx 
6 Sean Williams. 2019. “Marijuana Stock Goodwill Is a Potential $10 Billion Powder Keg”. 
https://www.fool.com/investing/2019/10/03/marijuana-stock-goodwill-is-a-potential-10-billion.aspx 
7 Sean Williams. 2019. “The Craziest Aurora Cannabis Statistic You'll Ever See”. 
https://www.nasdaq.com/articles/the-craziest-aurora-cannabis-statistic-youll-ever-see-2019-11-21 
Exhibit 8: Goodwill registered per company 
 
 








Hence, four of the biggest marijuana licensed producers have more than C$5.5 
billion in combined goodwill. The risk implied is better explained in the “Risks & 
Uncertainties” section.  
 
Shareholder structure 
Canopy Growth’s authorized share capital is an unlimited number of common 
shares of which 348,566,575 were issued and outstanding as at November 14, 
2019. 
After an investment of C$5 billion in 2018, the global beverage leader 
Constellation Brands Inc. (“Constellation”) became Canopy Growth’s major 
shareholder, owning 38% of the shares. As a result, Constellation has a 
significant influence and control over Canopy’s business and operations due to its 
ownership interest and its rights under the Second Amended Investor Rights 
Agreement.  
Having such a big private investor in the company has several implications. As an 
early stage company, Canopy will be receiving the support and expertise of a well 
stablished corporation in the areas of operations, product distribution and 
marketing, building long-term competitive advantages, that can potentially bring 
returns for the shareholders.  
However, Constellation is in a position to exercise significant impact over Canopy, 
including matters requiring shareholder approval, such as the election of 
directors, change of control transactions and the determination of other significant 
corporate actions. There can also be no assurance that the interests of 
Constellation will align with the interests of the Company or the Company’s 
shareholders. Hence, Constellation will have the ability to influence certain 
actions that may not reflect Canopy’s intent or the best interests or the Company 
or its shareholders. The presence of Constellation could limit the price that 
investors or an acquirer may be willing to pay for common shares and may 
therefore, delay or prevent a change of control or take-over bid of Canopy 
Growth. Pursuant to the Second Amended Investor Rights Agreement, 
Constellation also has certain consent rights which could delay or prevent the 
completion of certain transactions that may otherwise be beneficial to the 
Company’s shareholders.  
As a result, the Company may be dependent on Constellation, which could have 
a material adverse effect on the Company’s business, financial condition and 
results of operations.  
After an investment of 
C$5 billion in 2018, the 
global beverage leader 
Constellation Brands Inc. 
(“Constellation”) became 
Canopy Growth’s major 
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of the shares. 
 
 








This influence can be even greater in case Constellation exercises its potential 
warrants, where its ownership could push above 50% and Canopy Growth would 
receive an additional C$5.5 billion or more. 
Within insider shareholders, the director Murray Goldman has the highest 
percentage of shares, approximately 1.1%, followed by Bruce Linton, that despite 
being fired by the company in 2019, recently bought shares and now owns 0.75% 
of the Company, showing the confidence the ex-CEO has in the company. 
Other significant shareholders include the Vanguard Group, Morgan Stanley 




Even though the cannabis industry has been growing exponentially for the past 
few years, the slow regulatory processes and the noncompetitive prices of legal 
sources have prevented it from diluting the black market. In fact, as the cannabis 
industry is growing, the black market seems to be growing as well. 
According to the Barclays’ European Consumer Report8 and the United Nations9, 
the global cannabis market size, which is comprised of both the legal and black 
market, is estimated to be worth US $150 billion and is expected to increase to 
US $272 billion by 2028. Accounting for the US only, the black market for 
cannabis totals, approximately, US $70 billion. Hence, the estimated global legal 
market, valued at US $13,8 billion in 201810,  with an expected CAGR of 30-
35%11, is expected to be valued between US $87 and US $113 million in 2025. 
The main reason the black market still exists in countries where cannabis is legal 
has to do with price discrepancies. Illegal sellers have advantages in comparison 
to regulated companies given that they do not pay taxes or have to comply with 
regulatory requirements such as packaging and quality-control standards. As a 
result, marijuana prices on the black market can be well below legal prices, which 
along with the scarcity of licensed stores and the long process to obtain licenses, 
explains why one year after Canada legalized weed, 42% of people who 
consume the substance, still get cannabis from illegal sources12. 
 
8 420 Investor Daily. 2019. “Cannabis: Legal Market versus Black Market”. https://420investordaily.com/2019/12/05/cannabis-legal-market-versus-black-market/ 
9 Todd Campbell. 2019. “The Marijuana Industry: Everything you need to know”. https://www.fool.com/investing/marijuana-industry-investing-what-need-to-know.aspx 
10 Gran View Research, 2019. “Legal Marijuana Market Size, Share & Trend Analysis Report”. https://www.grandviewresearch.com/industry-analysis/legal-marijuana-
market 
11 Fortune Business Insights. 2019. “Cannabis/Marijuana Size, Share and Industry Analysis”. https://www.fortunebusinessinsights.com/industry-reports/cannabis-
marijuana-market-100219 
12 Statistics Canada. 2019.  
Exhibit 9: Legal Medical Cannabis 
Source:  
Prohibition Partners : “The Truth Behind the Global Cannabis Industry Slump” 
 
 








The average price per gram for legal marijuana in Canada dropped from C$10.64 
to $10.23, whereas on the black market, the average price dropped from C$5.9 to 
$5.59. Even though prices have been decreasing on both markets, illegal 
marijuana is 45% cheaper13.  
 
Medical Segment 
Medical marijuana uses the cannabis plant or chemicals in it to treat diseases or 
conditions. There is still a lot of research being done to understand cannabis 
properties and how they can help for medical purposes. The greatest amount of 
evidence for the therapeutic effects of cannabis relate to its ability to reduce 
chronic pain, nausea and vomiting due to chemotherapy. Part of its allure is that it 
is safer than opiates and far less addictive. 
In 2018, the global medical marijuana market solely was worth approximately US 
$13 billion and it is expected to grow at a CAGR of 23%, resulting in a market 
value of, approximately, US $44 billion by 202414. 
▪ Canadian Market 
According to Statista, the estimated total market size of medical marijuana in 
Canada in 2019 was C$1.7 billion and is expected to reach C$2.4 billion in 2025.  
According to Health Canada, in June 2019 there were 363,917 medical client 
registrations with federally licensed sellers, which represents an increase of 10% 
compared to the homologous year. Although there is a growth slowdown in the 
last couple of years, Health Canada estimated the market will eventually grow to 
450,000 people by 2024.  
As at March 31, 2019, there were approximately 73,600 registered Canadian 
patients with Spectrum Therapeutics, down from approximately 83,400 patients at 
December 31, 2018. The decrease is largely attributable to the partial 
cannibalization caused by the introduction of the Canadian recreational market.  
As reported by the 2018 Canada Marijuana Delivery Pricing Guide15, the price per 
gram for medical marijuana in Canada from illegal sources was, on average, 
C$8.18, whilst the price per gram from licensed marijuana in dispensaries could 
cost around C$9.12.  
 
 
13 Marijuana Business Daily. 2019. “Price gap grows in Canada between legal, illicit cannabis”. https://mjbizdaily.com/price-gap-grows-in-canada-between-
legal-illicit-cannabis/ 
14 IMARC Group. 2019. “Medical Cannabis Market.” https://www.imarcgroup.com/medical-cannabis-market 
15 Weed Smart. 2018. “Canada Marijuana Delivery Pricing Guide!”. https://weedsmart.ca/pricing-guide-canada-marijuana-delivery/ 
Exhibit 10: Medical Marijuana Clients 
registered in Canada 
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▪ International Market 
Currently, more than 30 countries around the world have legalized the therapeutic 
use of cannabis extracts and it is estimated that at least a dozen more will do so 
in the coming years.  
While there are 37 million people in Canada and 327 million in the United States, 
the European Union is home to almost 743 million citizens, constituting a potential 
big market for the industry, estimated to be €123 billion by 2028 from which €58 
billion derive from the medical segment16. 
Countries with newly legalized medical markets generally rely on imports to meet 
demand as they develop cultivation capacity and establish regulatory structures. 
The overall medical cannabis exports likely rank Canada third in global exports, 
behind the United Kingdom, home to Sativex-maker GW Pharmaceuticals, and 
the Netherlands, home to Bedrocan, which is authorized to export 1,500 
kilograms of medical cannabis to Germany annually. 
In Canada, exports of dried cannabis tripled to 1,460 kilograms in 2018, 
compared with 500 kilograms in 2017 and only 44 kilograms in 2016. Exports of 
medical cannabis oil, doubled to 920 liters, compared with 430 liters in 2017 and 
100 liters in 2016. 
 
Recreational Segment 
In the year following the legalization of recreational marijuana in Canada, the 
cannabis retail market has grown considerably, with legal retailers establishing 
more than 400 brick-and-mortar stores and generating $908 million in online and 
retail store sales17. According to The Canada Cannabis Report: 2019 Industry 
Update and Outlook18, the medical marijuana market in Canada is expected to 
reach C$ 5,2 billion by 2024, with an estimated CAGR of 22.5% between 2019 
and 2024. 
In the first months of legalization, Cannabis generated C$186 million in tax 
revenue in Canada. Under Canada’s legalization framework, the federal 
government receives 25% of the excise tax revenue, with the remaining amount 
going to the province where any given sale occurs. Statistics Canada also noted 
that general goods and services taxes on cannabis ranged between 5% and 15%, 
 
16 Health Europa. 2019. “Will Europe be the world’s largest medical cannabis market?” https://www.healtheuropa.eu/medical-cannabis-market/90033/ 
17 Statistics Canada. 2019. “The retail cannabis market in Canada: A portrait of the first year.” https://www150.statcan.gc.ca/n1/daily-
quotidien/191211/dq191211b-eng.htm 
18 New Frontier Data. 2019. “The Canada Cannabis Report: 2019 Industry Update and Outlook”. 
https://newfrontierdata.com/product/2019-canada-cannabis-report/ 
Exhibit 12: Canadian Dried Cannabis Exports 
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depending on the region. Nevertheless, those against cannabis legalization argue 
that it can be a gateway for more heavy and addictive drugs.  
The following countries are expected to legalize recreational marijuana in the 
upcoming years19: Mexico and New Zealand (2020); Australia, Luxembourg, 
Spain, Belgium, Portugal and the remaining states in the US (2023); Italy (2024); 
Holland, Germany, Colombia, Argentina, Peru, Ecuador and Chile (2025); 
France, Jamaica, Cuba, Barbados and South Africa (2026); Sierra Leone, Ghana, 
Zimbabwe and Lesotho (2027); Norway, Venezuela and Thailand (2029). 
In terms of pricing, due to taxes, recreational marijuana tends to be more 
expensive than medical marijuana. In the US, for example, in states where 
cannabis is legal, the tax on marijuana for medical patients is far lower than the 
tax rate for recreational consumers. The difference often ranges between 10% 
and 30%, and according to 2018 Canada Marijuana Delivery Pricing Guide, the 
price per gram for illegal recreational marijuana was C$7.42, and licensed 
marijuana in dispensaries, could cost around C$9.12.  
In the end, the legal market will never be able to fully capture the black market 
unless prices become competitive. However, with government taxes from sales of 
cannabis and the strict regulations on growth and sale of the substance, it is 
highly unlikely to happen, at least, in the upcoming years. 
▪ Cannabis 2.0  
Cannabis 2.0 refers to the Cannabis derivative products such as edibles, infused 
beverages, vapes, topicals and concentrates. Typically named “derivatives”, 
these products come with significantly higher margins than dried marijuana 
flower. 
The global market value for the CBD-infused edibles in 2017 reached, 
approximately, US $1 billion. However, by 2022, this market is already expected 
to be worth at US $4.1 billion, with an implicit CAGR of, approximately, 32.6%20.  
In terms of prices, it varies depending on the category and the amount of CBD 
and THC. For instance, a chocolate bar containing 300mg of THC could be found 




19 VICE. 2019. “These are the Countries Most Likely to Legalize Weed Next”. https://www.vice.com/en_us/article/gy4pa7/these-are-the-countries-most-
likely-to-legalize-weed-next 
20 PRNewswire. 2019. “Strong Demand for CBD Edibles to Create a $4.1 Billion Market by 2022” https://www.prnewswire.com/news-releases/strong-
demand-for-cbd-edibles-to-create-a-4-1-billion-market-by-2022--300890266.html 
21 Weedsmarte. 2019. “pricing guide Canada marijuana”. https://weedsmart.ca/pricing-guide-canada-marijuana-delivery/ 
 
 









▪ Main Competitors 
Competition is fierce in the cannabis industry and the emerging recreational 
segment and increasing legalization of Cannabis worldwide is driving the market. 
Hence, although Canopy Growth is considered the world’s largest cannabis 
company, it faces intense competition in the sector: Aurora Cannabis, Aphria Inc., 
Tilray and The Cronos Group. 
Table 1: Main Competitors in the Industry 










C$8,9 B C$226 M - C$259 M 24,360 22% 15  
C$2,9 B C$248 M - C$156 M 33,361 58% 25 
C$1,6 B C$237 M   C$17,5 M 13,398 32% 10 
Source: Companies Annual Reports 
*Cannabis gross profit, cannabis gross margin, distribution gross profit and distribution gross margin are non-GAAP 
financial measures that do not have any standardized meaning prescribed by IFRS and may not be comparable to 
similar measures presented by other companies. Due to technical difficulties in Tilray’s website, it was not possible to 
gather information on the company. Cronos Group still has not presented its annual results for 2019, therefore we 
could not compare information. 
Nevertheless, due to price discrepancies and supply constraints, the biggest rival 
that Canopy Growth faces is the Black Market. 
Licensed marijuana producers are still taking some sales away from the black 
market since the legalization of recreational use has converted some costumers 
to more reliable and better-quality products that regulated companies can 
provide. Also, the production capacity for the major marijuana growers is 
increasing and therefore there will be enough production to meet the demand.  
▪ SWOT Analysis 
In order to further analyse Canopy Growth competitive environment, a SWOT 
Analysis was designed to assess the potential gaps between the external 
opportunities and threats and the internal strengths and weaknesses of the 
company business model, also serving as an indicator for the future prospect.  
Strengths 
• Size: With over 4.8 million square feet of indoor and greenhouse production 
capacity, in 2019 Canopy harvested 46,927 kilograms of cannabis, allowing 
the firm to achieve significant economies of scale and to be one of the least 
cost producers in the space. Canopy is only exceeded by Aurora Cannabis, 
 
 








which has ramped up its production capabilities over the past year, 
producing 57,442 kilograms. 
• Vertically integrated: Operations from genetic diversification all the way to 
the production of cannabis derived consumer staples, allowing them to 
control the entire production chain and to offer higher margin, value added 
products.  
• Cannabis best-established brands: Tweed has positioned itself as one of 
the most recognisable brands in the cannabis market, trying to transcend the 
pharmaceutical market to establish itself as a lifestyle brand. 
• Strategic partnerships: Canopy has been able to foster important 
relationships with public figures such as the rapper Snoop Dogg, through his 
business Merry Jane, a cannabis lifestyle company and information network. 
These initiatives drive Canopy’s brand image, which can hopefully increase 
consumer engagement and build fidelity.  
• Strong R&D portfolio: C$154 million registered in Intellectual property, with 
130 issued patents and over 300 patent applications. In comparison, Aurora 
Cannabis had 101 patent applications. The Canadian patent database, 
administered by the Canadian Intellectual Property Office, yielded 345 
patent applications related to the search term “cannabis” in 2018.q 
Weaknesses 
• Significant dilution of original shareholders: The large-scale funding 
rounds proportionated an extremely fast growth in expense of early investors 
who get their investments diluted. In total, Canopy has issued nearly C$1 
billion in equity. 
• Rely heavily on share-based compensation: Share-based compensation 
expense was $182,837 in fiscal 2019, as compared to $29,631 in fiscal 
2018. The year-over-year increase of $153,206 is mainly attributable to the 
continued increase in the number of stock options granted, which is primarily 
attributable to the increase in the number of employees of the Company, 
from approximately 1,000 at March 31, 2018 to approximately 3,200 at 
March 31, 2019. 12.8 million stock options were granted in fiscal 2018, as 
compared to 22.1 million in fiscal 2019. Even though this does not represent 
actual cash-based expenditures, it does present a clear signal to the market 
that Management is perhaps over compensated or too focused on paying 
themselves out versus ensuring the success of the firm. However, this 
strategy is a way to have everybody aligned, working hard, and wanting to 
make the company successful. 
 
 









• Continuous growth through organic sales and acquisitions: Smaller 
producers will have a harder time competing at scale with Canopy, making 
them easy targets for corporate takeovers. This is coupled with low interest 
rates in the Canada, which means that there is both an abundance of cheap 
capital and opportunities for consolidation;   
• New markets: Its position and recognition worldwide means that, should 
new markets open to the recreational cannabis sector, Canopy’s expertise 
should give it a clear advantage in the international market.  
Threats 
• High Taxes: Higher taxes increases prices and makes legal business less 
competitive in relation to the black market.  
• Regulatory Agency Health Canada as a main source of supply 
problems: In January 2019, the agency tasked with reviewing and 
approving or denying cultivation, processing, distribution, and sales license 
applications, was working with a backlog of more than 800 applications22. 
• Intense M&A environment: Canopy’s largest competitors continue to grow 
organically but most importantly through acquisitions. There is an inherent 
risk of take-overs in the market.  
• International regulation ambiguity: Restricted shareholder pool as 
institutional investors shy away from the sector.  
• Commoditization risks/low product differentiation steaming from plain 




Since the legal cannabis industry is a recent, emerging industry, the forecasted 
years had to be extended in order to produce a proper forecasting. Hence, 
instead of doing a typical 10-year forecast, we will be doing a 20-year forecast 
and assume a growth rate for the FCF in perpetuity. For the following analysis, 
please refer to table 1 (in appendix), which represents the following analysed 














In order to forecast the revenues of the company, we used a bottom-up 
approach, i.e. the value drivers were price (per gram) x quantity (in kilograms). To 
simplify the forecast and make it more accurate, we distinguished revenues 
between segments, from medical revenues to recreational revenues and, from 
international sales to Canada sales. 
Recreational Revenues 
The trickiest forecast is for recreational revenues, since it is a relatively new 
market. The company only had recreational sales in 2019 and only in Canada, 
since most countries have not legalized marijuana for recreational purposes. 
According to the market analysis done previously, we know that revenues are 
expected to increase at a relatively high CAGR, close to 30-35%. 
Considering Canada sales, we expect quantities sold to increase by 30%, 
decreasing around 5% every 5-6 years. This would lead to a quantity sold of 
almost 1.5 million kg in 2040, in opposition to 16 thousand kg in 2019. In terms of 
pricing, in 2019, the average price for licensed marijuana sold in dispensaries in 
Canada was, around, C$9.12. Therefore, we used this value as a starting point 
for prices in the upcoming year (2020). Nonetheless, since the black-market price 
for marijuana was around C$7.42, the price is expected to drop to a value closer 
to that one (in order for it to be competitive). Hence, we assume a decrease in 
prices of 2% for 15 years and 1% for the remaining 5 years forecasted, obtaining 
a price of C$7.45 in 2030 and C$6.41 by 2040, when we expect it to stabilize. 
Overall, Canada sales of recreational marijuana are forecasted at C$9.41 billion 
in 2040, versus C$140.5 thousand in 2019. 
The quantities of recreational marijuana sold internationally are expected to 
increase by 35% for the next 5 years, eventually stabilizing at a CAGR of 15% in 
the last 5 years of the forecast. Sales are expected to begin in the next fiscal 
year, 2020 since other adult-use products, such as their “First and Free” line are 
already being sold in the US, in the states where recreational marijuana is legal. 
This would result in sales of C$12.47 billion by 2040. 
Medical Revenues 
In Canada, quantities sold of medical marijuana have decreased, mostly due to 
the high prices of marijuana in the legal dispensaries (in opposition to the black 
market). For this segment, we still believe that when the company obtains more 
licenses for production facilities, quantities sold will still increase. Therefore, we 
assumed an initial growth of 23% (based on industry growth for the medical 
segment), which eventually decreases to 10% in the last forecasted years. In 
Exhibit 14: Recreational revenues by 
segment (historical and forecasted) 
Source: Company Report and our estimates 
Exhibit 15: Price of recreational marijuana 
(historical and forecasted) 
Source: Company Report and our estimates 
Exhibit 16: Quant. sold of recreational 
marijuana (historical and forecasted) 
Source: Company Report and our estimates 
Exhibit 17: Medical revenues by segment 
(historical and forecasted) 
Source: Company Report and our estimates 
 
 








terms prices, since we have found that the average price for medical marijuana in 
Canada was C$10.23, we use it as a starting point. However, we assume a 
decrease of 1% in the first 5 years and 2% the following 10 years. In 2040, the 
price is expected to be $7.56, closer to black market prices. Overall, sales are 
expected to increase from C$68.8 million in 2019 to C$2.6 billion in 2040. 
International sales, on the other hand, are expected to grow at a higher rate, as 
the market is not as established as in Canada and there is still potential growth 
arising from legalization in other countries. Therefore, we assume a CAGR closer 
to that of the recreational segment, 30%. Eventually, the expected growth 
decreases to 10% in the last forecasted years. In terms of pricing, even though in 
2019 prices are higher for medical marijuana (C$14.74 in 2019), by 2040, it is 
expected to become cheaper than recreational marijuana since sales tax on the 
latter tend to be higher than on medical marijuana. Hence, a 2% decrease is 
expected for the next 5 years, followed by a 5% decrease in the 10 years after. 
By 2040, the price is expected to be close to C$6.85, which is more in line with 
black market prices (still considering the excise tax on these products). In that 
sense, total medical revenues, which amounted to C$78.9 million in 2019, are 
expected to become close to C$3 billion by 2040. 
Excise taxes 
When the company started selling marijuana for recreational purposes, 
government implemented a tax on those sales, which was, approximately, 19%. 
The average excise tax in the US, based on the excise taxes of the states where 
it is legal is 18%23. Based on this information and considering that the typical tax 
on these sorts of products (tobacco, alcohol) is close to 15%, we assumed a tax 
rate of 18% for the upcoming years, eventually decreasing to 15% in the long-run.  
Other Revenue 
This segment of the Income Statement comprises other CBD-infused products, 
besides dry buds and oils. As previously mentioned, the potential of the sector is 
huge, since it is an industry in the beginning of its form, and, therefore, the 
potential CAGR in the upcoming years is, approximately, 33%. With the launch of 
its CBD-infused products line, “First & Free” (now available in the United States) 
and C$5 billion investment of Constellation Brands, this segment “Other 
Revenue” is expected to grow close to industry values. Therefore, we assumed 
33% growth in the upcoming years, which slowly decreases in the future, 
stabilizing in 2040 to 15% growth. The initial revenue of almost C$35 million in 
2019 is expected to hit C$2.67 billion by 2040.  
 
23 Medical Marijuana Inc., Marijuana Prices and Sizes, October 9, 2019 
Exhibit 19: Quant. sold of medical marijuana 
(historical and forecasted) 
Source: Company Report and our estimates 
Exhibit 21: COGS segmentation in 2019 
Source: Company Report 
Exhibit 20: Other revenue (historical and 
forecasted) 
Source: Company Report and our estimates 
 
 








Overall, there is a substantial increase in revenues (from C$226 million in 2019 to 
C$24 billion in 2040) due to the high potential and growth of the industry.   
▪ Cost of Goods Sold 
In the Income Statement of the company, there is one important variable cost that 
is accounted for prior to operating expenses, inventory production costs 
expensed to cost of sales. We measured these costs as a percentage of total net 
revenues. Apart from the recurring costs of recreational and medical marijuana 
sold, there was a major increase in these costs in fiscal year 2019 (from C$40 
million to C$175 million) due to the operating costs of facilities that had unutilized 
capacity. Therefore, in the subsequent years, Canopy Growth should be able to 
reduce these costs through the usage of greenhouses to full capacity. While in 
2017, these costs represented only 38% of revenues, this value increased to 78% 
in 2019. We assume a decrease of 5% for the upcoming years, eventually 
reaching 8% by 2040, with an ending weight of 19% of total revenues. 
▪ Operating Expenses 
The majority of costs associated with operations are fixed costs. Therefore, it did 
not make sense for us to use revenues as the driver for their potential growth. 
Hence, to different costs we attributed different value drivers, depending on their 
nature. A great part of the operating expenses is employees' compensation. In 
March 31, 2019, employee compensation and benefits were $158,161 (for the 
year ended March 31, 2018 – $49,971), without even considering share-based 
compensation expenses. Meaning that, around 50% of sales and marketing, 
research and development and general and administration expenses were 
comprised of employees' compensation. Therefore, it made sense for us to use 
the #employees x compensation per employee as the drivers for these three 
captions in the Income Statement. Notice that, not all costs are associated with 
employees, we simply found it to be the most appropriate driver. 
Sales and marketing 
Sales and marketing are sizeable costs for the company. There was an increase 
in these expenses in 2019 (from C$38 million to C$154 million) due to strong 
investments made by the company on their marketing and promotional 
campaigns, mostly focused on brands Tweed and Tokyo Smoke. Canopy Growth 
has been betting on marketing and other promotion in anticipation their entrance  
in the recreational market (particularly in Canada). The major cost of the caption 
was related to staffing in marketing and sales functions, which was required to 
service the regulated recreational and international markets. Other expenses 
included a customer care centre, cannabis retail and education programs and a 
Exhibit 23: Gross Margins of Cannabis 
companies 
Source: Companies Reports 
Exhibit 22: COGS and Gross Margin 
(historical and forecasted) 
Source: Company Report and our Estimates 
Exhibit 25: Sales and marketing expenses 
(historical and forecasted) 
Source: Company Report and our estimates 
Source: Companies Reports 
Exhibit 24: Relevant Operating Expenses 
segmentation on March 31, 2019 
 
 








medical outreach program. With the acquisition of C3 in May 2019 (which already 
has a robust sales and marketing organization) and the continuous bet on 
promoting recreational marijuana consumption as well as providing these 
additional services, we believe the cost per employee will slightly decrease in 
comparison with the last year. Therefore, we assumed a cost of C$35k per 
employee which we decreased by C$5k every five years. This implies an initial 
forecasted value of C$255 million for 2020 (C$35k per employee) and an ending 
value of C$4.83 billion for 2040 (C$20k per employee). 
Research and development 
R&D, when compared to other operating expenses, is relatively small (C$15 
million in 2019). According to the fiscal year 2019 financial report of the company, 
it will continue to invest in hiring advanced degree researchers and engineers, in 
areas of vapers’ R&D, plant genetics, cannabis-based medical therapy clinical 
research. Therefore, it will also incur in higher compensation costs associated 
with the teams conducting R&D, product and system development and testing. 
Not only do pharmaceutical companies tend to have high R&D costs, but it is also 
crucial in such an early stage of the cannabis industry for companies to gain any 
sort of competitive advantage over their peers, by developing more advanced, 
target-oriented products. Hence, we assume the cost per employee will increase 
in the upcoming years (due to these investments), from $5k per employee to $7k. 
However, it will be slowly decreasing in the long run, to a value of $3k per 
employee as the industry matures, and the developed products already satisfy 
customers’ needs and expectations. Overall, the initial value of C$15 million in 
2019 is expected to increase to an ending forecasted value of C$684 million) 
 General and administrative 
General and administrative is the second largest operating cost of the company. 
In fiscal year 2019, the company incurred in compliance costs regarding its 
listings on the TSX and NYSE (extraordinary costs), services fees and other 
costs regarding the international expansion of and costs with personnel. As the 
international market is currently still in expansion with the legalization of medical 
and recreational marijuana in other countries (particularly in the United States 
and Europe), the company is expected to continue to incur in costs regarding the 
expansion of its operations in the upcoming years. Nonetheless, in the long run, 
we believe these costs will decrease since the company will slowly get more 
established in the market. Hence, the initial value of C$168 million (C$53k per 
employee) is expected to increase to C$6.377 billion (C$28k per employee). 
 
Exhibit 26: R&D expenses (historical and 
forecasted) 
Source: Company Report and our estimates 
Exhibit 27: General and administrative 
expenses (historical and forecasted) 
Source: Company Report and our estimates 
 
 








Share-based compensation expense 
Compensation based on shares is the most relevant cost for the company. There 
has been an increase in this expense mostly due to: a continuous increase in the 
number of stock options granted; an increase in stock price and the Omnibus 
Incentive Plan (i.e. type of equity incentive plan where the company has flexibility 
to grant any type of award out of the plan). Linton (former co-CEO) believed that 
the best way to install loyalty in his rapidly growing employee base was to provide 
them with long-term-vesting stock. However, with the growth in the number of 
employees, there is more damage due to share-based compensation. Therefore, 
and since the company is far from being profitable, we believe that, in the long 
hall, there will be a decrease in the compensation per employee in shares as it is 
the only way to decrease such a huge expense. The forecasting value goes from 
C$57k per employee in 2019 (C$183 million) to C$11k in 2040 (C$2.57 billion). 
Overall, the expected increase in revenues and decrease in costs as the industry 
expands, leads to an increase in EBIT value. While, in 2019, EBIT had a negative 
value (-C$520 million) and the EBIT margin was -230%, in 2040, these values are 
expected to revert to positive ones (C$10.93 billion and 45%, respectively). 
▪ Taxes 
The statutory tax rate in Canada is, and has been for the past years analysed, 
26.5%. However, the total amount of taxes charged in every year is higher than 
the established due to “Tax Adjustments”. The majority of tax adjustments are 
non-recurring, and therefore the forecasting value is zero. However, tax 
adjustments on non-deductible expenses are expected to be recurring since, 
usually, share-based compensation expenses are non-deductible for taxes 
purposes, particularly when regarding incentives to personnel. Given that the 
company comprises two share-based compensation expenses’ captions in the 
operating expenses, we felt it made more sense to use them as a proxy to 
estimate these taxes, rather than total operating expenses. Hence, in the 
forecasting years, we decided to use the past years’ average percentage (32.5%) 
and applied it to the future. The value of this tax adjustments is expected to 
increase from C$99 million in 2019 to C$833 million in 2040). 
The resulting NOPLAT from the deduction of taxes in the EBIT values are 
expected to be positive only from 2033 onwards. As mentioned previously, the 
company has very high costs and insufficient revenues to cover them, since the 
market is still very restrict internationally. Only when new markets emerge 
(cannabis is legalized in more countries) and costs decrease (with economies of 
scale) will the company be able to produce a positive net income.  
Exhibit 28: Share-based compensation 
expense (historical and forecasted) 
Source: Company Report and our estimates 
Exhibit 29: EBIT, Taxes and NOPLAT 
(historical and forecasted) 
Source: Company Report and our Estimates 
 
 









Free Cash Flow 
Having established NOPLAT, we can now calculate Free Cash Flow from 
operations. The following forecasted items required for the calculation are 
represented in table 2 (in appendix) and the resulting FCF after the forecasting 
will be presented in table 3 (in appendix). 
▪ Net Working Capital 
Inventory 
Inventory is a very large asset for Canopy Growth. This is very common in the 
cannabis industry. As shown in exhibit 31, comparables of Canopy, such as 
Aphria and Aurora also suffered large increases in their inventory levels, even if 
less than Canopy. According to an article on the Motley Fool24, the large 
inventories can be explained by the lag of sales growth when comparing to the 
increase in production; the delay of Health Canada in providing licenses to retail 
dispensaries, which limits the access to legal cannabis; and the high excise 
taxes. The preceding two reasons push consumers away from the legal market 
and encourage purchases on the black market.  
With the new line “First and Free” Canopy launched and the potential expansion 
of medical and recreational marijuana sales to international markets, we believe 
inventory values will slowly decrease, in percentage of operations’ size. To 
forecast this caption, we used the holding period as a driver for inventory value 
and we assumed a decrease of 5% per year in that period. Moreover, since the 
cannabis’ expected life cycle is approximately 90 days, it can be harvested 
between 3 to 4 times a year. The higher the harvest frequency, the more 
justifiable it is having lower relative inventory levels. Overall, the holding period is 
expected to decrease from 314 days in 2019 to 118 in 2040. 
Accounts Receivable 
In this industry, and particularly with Canopy Growth, most transactions related to 
medical sales are done using credit cards (amounts receivable is not expected to 
decrease a lot). Recreational sales are done through Canadian/territorial 
agencies, which have low credit risk, assuring the company the payment of their 
products. Therefore, the company is not expected to demand earlier payments. 
Hence, for this caption we took the average collection period (98 days) from past 
years and forecasted it to the future, as there is no reason to assume differences.  
 
24 The Motley Fool, This One Chart Shows Why You Should Avoid Canadian Cannabis Stocks Like the Plague, October 2019 





Exhibit 32: Working capital composition in 
2019 vs 2040 
AR 
Source: Companies Reports 
Exhibit 31: Inventory levels per company 
Source: Company Report and our estimates 













Accounts Payable and Accrued Liabilities 
Accounts payable and accrued liabilities was mostly comprised of amounts of 
property, plant and equipment; professional fees; compensation-related liabilities 
and other miscellaneous liabilities. To calculate the average payable period, we 
used the pharmaceutical industry benchmark (71 days) as proxy for future years. 
These results considered lead do an ending cash conversion cycle of 145 days 
and an operating cycle of 216 days. 
▪ Capital Expenditures 
PP&E 
In order to forecast PP&E, we first looked at the current facilities owned by 
Canopy Growth in order to conduct its operations. Afterwards, we have calculated 
the average kilograms produced per square-foot, so that we could get the square-
feet required to produce the quantities sold. Then, we were required to multiply 
the average PP&E in C$ thousand per square-foot, to get the total amount. 
Goodwill 
As mentioned previously, the increase in goodwill is attributable to Canopy’s 
strong M&A activity and their preference for acquiring targets with strong brands. 
Canopy Growth intends to continue with these acquisitions (plan to acquire 
leading multi-state operator Acreage Holdings, Inc). Since it is fairly difficult to 
forecast either: 1) future goodwill impairments or 2) future acquisitions where the 
company pays in excess of book value for the assets acquired; we assumed the 
last value (C$1.54 billion) as constant forever. 
Intangible Assets 
Licenses are a major part of the business, as the company needs them to be able 
to cultivate cannabis. Moreover, patents are very important in the industry also 
since they give the company comparative advantages, putting them ahead of  
their peers. However, it is more of an up-front investment, since the company 
obtains these licenses now and in the upcoming years. Therefore, in the long run, 





Source: Company Report and our Estimates 
Exhibit 33: Cash conversion and Operating 
cycles (historical and forecasted) 
Source: Company Report and our Estimates 













Discounted Cash Flows (DCF) 
Discount Rate 
In order to discount the cash flows of the company, we used WACC (weighted 
average cost of capital). By doing so, we are assuming the capital structure of our 
company will hold until perpetuity, i.e. the Debt-to-Equity ratio will remain 
constant. The first input was Beta, which we calculated through a regression 
where the independent variable is the market risk premium (MRP) and the 
dependent variable is the company’s stock’s excess return. The market risk 
premium resulted from the difference between the S&P500 returns (the majority 
of shareholders of the company are American) and, consequently, the US 
Government 10-year bond. The resulting beta from the regression was 0.97, with 
a 95% confidence interval between 0.72 and 1.22. To calculate the beta, we used 
daily observations from the last 5.5 years (from 08/04/2014 until 15/11/2019). 
From the CAPM equation, considering the beta calculated, the MRP and the 
Canadian Government 10-year bond, we obtained a cost of equity (re) of 6.41%. 
Considering a cost of debt (rd) of 5.85%, obtained from the average YTM of the 
company’s current debt obligations, a Debt/EV of 0.17 and an Equity/EV of 0.83, 
we attain a WACC of 6.05%. The tax rate used was 26.5% (statutory tax rate). 
Growth Rate 
The growth rate used was 3.6%, which was calculated based on the expected 
long-term inflation rate (approximately, 2.15%) and the expected real growth of 
the industry (around 1.4%). The legal cannabis industry is at a very initial stage 
and it will capture almost entirely the illegal market, meaning that it will still have 
positive real growth past the last forecasted year. 
 Enterprise Value and Share Price 
Upon finding the terminal value of the company, using the growth rate and WACC 
calculated, and discounting the FCF we obtain an Enterprise Value (EV) of 
C$16.62 billion. After deducting debt of, approximately C$1.86 billion and minority 
interests of C$7.01 billion (42%), the resulting Equity Value was close to C$7.75 
billion. With, approximately, 267 million shares outstanding, the share price of the 
stock obtained was C$29.02. Hence, based on out model, our recommendation 
for institutional and individual investors is to hold the stock, since the current 
share price (22/12/2019) is C$27.31, which yields a return of, approximately, 6%. 
The company has growth potential in the future, however, at the moment, it is still 
unable to provide high returns to investors. 
Source: Company Report and our Estimates 
Exhibit 37: Enterprise Value composition 
Source: Bloomberg  and our Estimates 
Exhibit 35: 3-year Rolling beta of Canopy  
Source: Company Report and our Estimates 












▪ Sensitivity Analysis 
In order to understand the impact of alterations in growth and WACC values on 
the share price, we decided to conduct a sensitivity analysis. As it is visible in 
exhibit 38, the share price can range from negative to C$130. In the case of 
negative share prices, the company would go bankrupt and, therefore, its value 
would be zero. Overall, the share price is more volatile with WACC than with 
growth, i.e. changes in WACC will be more impactful on the share price. At the 
current WACC (6.05%) and expected growth rate (3.6%), we still recommend 
investors to hold it. However, if the growth rate falls too beneath the expected or 
WACC increases, the recommendation could turn to “sell”. 
 
 Relative Valuation Approach 
A second approach used to value the company was the relative valuation, or 
Multiples approach. The comparables used in the calculation of the multiples 
were: Canopy Growth Corporation; Aurora Cannabis; Aphria; Tilray and Cronos 
Group (all quoted on the NYSE). The average and median multiples obtained are 
showed in exhibit 39 and, when applied to Canopy’s Growth data estimate an 
Enterprise Value range of $5.33 billion to $25.22 billion. The average value for 
the EV of the company was, therefore, estimated to be $16.13 billion, which, 
converted to Canadian dollars at the current exchange rate 1:1.3 (31/Dec/2019) 
totals C$20.96 billion. Deducting previously mentioned debt values and minority 
interests, we obtain an expected share price of C$42, approximately, C$13 above 
the share price estimated using the DCF method. 
 
Risks & Uncertainties 
The company’s valuation is subject to the uncertainty regarding future legislation 
of recreational and medical marijuana in other countries. The lack of adherence 
from governments to changes concerning marijuana laws may lead to a lower 
growth of quantities sold by the company and, therefore, compress revenues. 
The amount allocated to certain acquisitions beyond the value of their physical 
assets is also a risk and the companies not able to recover the value of goodwill 
by developing its acquired assets and monetizing its purchased patents might 
expect a big write down. Alongside goodwill, there is the risk of oversupplying the 
market due to intense competition, leading to large accumulated inventories and 
major losses due to product waste (expired products). Moreover, the intense 
competition, combined with the taxation on marijuana products may lead to 
(in million $)
EV/Sales 76.3x 42.2x 17 273 9 559
EV/EBITDA -61.0x -103.5x 14 509 24 637
EV/EBIT -79.4x -94.9x 21 098 25 216
P/Sales 0.2x 0.1x 11 365 5 329
Multiple Range EV Range
Exhibit 39: Multiples Analysis 
Source: Our Estimates 
Exhibit 38: Sensitivity Analysis 
Source: Our Estimates 
29.02C $ 5.45% 5.75% 6.05% 6.35% 6.65%
3.0% 37 23 12 3 -4
3.3% 51 33 20 9 1
3.6% 68 46 29 16 7
3.9% 93 63 41 25 13



















compressed margins, as the company may not be able to decrease prices and 
make them competitive with the black market. With international expansion, 
emerges another risk for the company’s cash flows: foreign exchange risk. Due to 
fluctuation in exchange rates and the large operations expected for the 
international market, the company might suffer erosions in its profits overseas. 
Given the market is still emerging, it is also important to bear the risk associated 
to the volatility Canopy’s cash flows have been subject to and consider that it is a 
reality that might still follow the company in the upcoming years. Lastly, our 
recommendation was based on our own analysis of the company and, therefore, 











































FORECASTING REFORMULATED INCOME STATEMENT
Fiscal Year Ending March 31
(Expressed in CDN $000's)
Core 2015A 2016A 2017A 2018A 2019A 2020F 2021F 2022F 2023F 2024F 2025F 2030F 2035F 2040F
Revenues
Recreational revenue 140 532 406 192 527 951 686 453 892 854 1 161 726 1 512 094 4 688 439 11 779 644 21 882 488
Canada 140 532 192 660 245 449 312 702 398 382 507 539 646 604 1 783 689 4 920 391 9 411 628
Quantity (kg) 16 250 21 125 27 463 35 701 46 412 60 335 78 436 239 367 730 489 1 469 274
Price (per gram) 8.65 9.12 8.94 8.76 8.58 8.41 8.24 7.45 6.74 6.41
International 213 532 282 502 373 751 494 472 654 187 865 489 2 904 750 6 859 253 12 470 860
Quantity (kg) 16 250 21 938 29 616 39 981 53 974 72 866 270 545 825 637 1 660 650
Price (per gram) 13.14 12.88 12.62 12.37 12.12 11.88 10.74 8.31 7.51
Medical revenue 2 371 12 699 39 895 74 349 78 850 106 452 130 431 159 851 195 957 240 281 293 707 713 519 1 568 191 2 959 131
Canada 2 371 12 699 39 860 70 617 68 759 92 157 112 220 136 650 166 399 202 624 245 732 600 230 1 350 063 2 582 375
Quantity (kg) 324 1 696 5 136 8 421 7 324 9 009 11 080 13 629 16 764 20 619 25 259 68 255 169 841 341 610
Price (per gram) 7.31 7.49 7.76 8.39 9.39 10.23 10.13 10.03 9.93 9.83 9.73 8.79 7.95 7.56
International 35 3 732 10 091 14 295 18 211 23 201 29 558 37 657 47 975 113 289 218 128 376 755
Quantity (kg) 3 287 746 970 1 261 1 639 2 131 2 770 3 601 10 989 27 344 54 998
Price (per gram) 11.67 13.00 13.53 14.74 14.44 14.16 13.87 13.60 13.32 10.31 7.98 6.85
Other revenue 3 599 34 049 45 149 59 868 79 384 103 200 134 160 174 407 532 249 1 324 406 2 663 854
Excise taxes (27 090) (71 229) (92 580) (120 374) (153 437) (195 650) (249 563) (713 730) (1 793 239) (3 331 215)
% Recreational revenues 19% 18% 18% 18% 17% 17% 17% 15% 15% 15%
Total Revenues 2 371 12 699 39 895 77 948 226 341 486 564 625 670 805 314 1 038 574 1 340 517 1 730 645 5 220 476 12 879 003 24 174 258
Inventory production costs expensed to cost of sales (2 400) (12 796) (15 293) (40 213) (175 425) (358 255) (437 644) (535 136) (655 632) (803 930) (986 002) (2 228 755) (3 623 877) (4 483 153)
% Revenues 101% 101% 38% 52% 78% 74% 70% 66% 63% 60% 57% 43% 28% 19%
Fair value changes in biological assets included in inventory sold and other inventory charges(5 721) (19 722) (34 978) (67 861) (129 536) (144 564) (159 381) (175 885) (194 478) (215 217) (238 223) (339 376) (330 391) (244 723)
% Inventory 131% 89% 76% 67% 49% 47% 45% 42% 40% 38% 36% 28% 22% 17%
Unrealized gain on changes in fair value of biological assets 8 576 38 805 49 090 96 721 167 550 597 885 730 376 893 079 1 094 173 1 341 665 1 645 522 3 840 818 7 331 855 11 799 282
% Revenues 150% 197% 140% 143% 129% 123% 117% 111% 105% 100% 95% 74% 57% 49%
Total COGS 455 6 287 (1 181) (11 353) (137 411) 95 066 133 351 182 058 244 062 322 518 421 296 1 272 688 3 377 587 7 071 407
Gross Margin 2 826 18 986 38 714 66 595 88 930 581 629 759 021 987 372 1 282 636 1 663 034 2 151 942 6 493 164 16 256 589 31 245 665
% Revenues 119% 150% 97% 85% 39% 120% 121% 123% 123% 124% 124% 124% 126% 129%
Sales and marketing (2 685) (5 653) (12 960) (38 203) (154 392) (255 446) (328 477) (422 790) (545 251) (703 771) (623 032) (1 305 119) (2 833 381) (4 834 852)
Cost per employee (36) (36) (24) (37) (48) (35) (35) (35) (35) (35) (30) (25) (22) (20)
Research and development (267) (721) (810) (1 453) (15 238) (37 535) (52 127) (72 461) (98 122) (126 649) (130 806) (276 278) (420 553) (684 213)
Cost per employee (4) (5) (1) (1) (5) (5) (6) (6) (6) (6) (6) (5) (3) (3)
General and administration (4 875) (8 177) (16 858) (43 819) (168 434) (414 892) (576 187) (800 954) (1 084 599) (1 399 922) (1 445 871) (3 053 848) (4 294 907) (6 766 877)
Cost per employee (65) (52) (31) (42) (53) (57) (61) (66) (70) (70) (70) (58) (33) (28)
Acquisition-related costs (1 155) (7 369) (3 406) (23 394) 189 680 208 648 104 324
% Acquisitions 13% 2% 8% 1% 6% 6% 6% 6% 6% 6% 6% 6% 6%
Share-based compensation expense (1 559) (3 110) (8 046) (29 631) (182 837) (396 158) (483 947) (591 754) (724 999) (860 914) (818 038) (1 131 750) (1 627 054) (2 566 078)
Compensation cost per employee (21) (20) (15) (29) (57) (54) (52) (49) (47) (43) (39) (22) (13) (11)
Share-based compensation expense related to acquisition milestones (1 000) (387) (690) (19 475) (100 164) (195 320) (235 951) (221 425) (128 540) (42 623)
% Acquisitions 27% 4% 0% 45% 6% 6% 6% 6% 6% 6%
Depreciation and amortization (646) (2 256) (6 064) (12 889) (21 510) (47 689) (63 625) (84 994) (106 414) (133 476) (167 631) (449 972) (1 053 196) (1 718 446)
% PP&E and Intangible assets 4% 3% 2% 3% 1% 3% 3% 3% 3% 3% 3% 3% 3% 3%
Total Operating Expenses (11 032) (21 459) (52 797) (148 876) (665 969) (1 157 360) (1 531 667) (2 090 054) (2 687 925) (3 267 355) (3 185 379) (6 216 966) (10 229 091) (16 570 465)
Other (expense) income, net - Core (1 191) (481) (1 193) (21 620) 57 110 (122 026) (156 233) (200 046) (256 165) (328 053) (420 145) (1 192 040) (2 400 475) (3 742 018)
Foreign currency loss (2 440) (5 572) (122 026) (156 233) (200 046) (256 165) (328 053) (420 145) (1 192 040) (2 400 475) (3 742 018)
% International revenues 65% 55% 54% 52% 50% 49% 47% 46% 39% 34% 29%
EBIT (9 397) (2 954) (15 276) (103 901) (519 929) (697 756) (928 880) (1 302 728) (1 661 454) (1 932 374) (1 453 582) (915 842) 3 627 024 10 933 182
% Revenues -396% -23% -38% -133% -230% -143% -148% -162% -160% -144% -84% -18% 28% 45%
Taxes
Statutory taxes 2 490 783 4 048 27 534 137 781 184 905 246 153 345 223 440 285 512 079 385 199 242 698 (961 161) (2 897 293)
Statutory tax rate 26.5% 26.5% 26.5% 26.5% 26.5% 26.5% 26.5% 26.5% 26.5% 26.5% 26.5% 26.5% 26.5% 26.5%
Taxes Adjustments (2 477) (1 019) (20) (15 516) (182 171) (193 767) (235 950) (266 858) (280 757) (298 019) (271 570) (385 287) (572 107) (915 370)
Non-deductible expenses (937) (935) (2 156) (19 310) (99 192) (192 119) (233 831) (264 130) (277 239) (293 479) (265 708) (367 605) (528 486) (833 491)
% Share-based compensation expenses (non-deductible) 36.6% 26.7% 24.7% 39.3% 35.1% 32.5% 32.5% 32.5% 32.5% 32.5% 32.5% 32.5% 32.5% 32.5%
Increase in unrecognized temporary differences - Core (1 762) 335 2 258 (5 506) (77 158)
Rate differential (4 060)
Non-taxable portion of capital gains and losses 9 421
Other 222 (419) (122) (121) (1 761) (1 648) (2 119) (2 728) (3 518) (4 540) (5 862) (17 682) (43 621) (81 878)
% EBIT -2.4% 14.2% 0.8% 0.1% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3%
Total Taxes 13 (236) 4 028 12 018 (44 389) (8 861) 10 203 78 365 159 529 214 060 113 629 (142 589) (1 533 268) (3 812 663)
Other comprehensive income - Core 198 410 40 617
NOPLAT (9 384) (3 190) (11 050) (91 473) (523 701) (706 618) (918 677) (1 224 363) (1 501 925) (1 718 315) (1 339 952) (1 058 431) 2 093 755 7 120 519
 
 





























































FORECASTING REFORMULATED BALANCE SHEET
Fiscal Year Ending March 31
(Expressed in CDN $000's)
Core 2015A 2016A 2017A 2018A 2019A 2020F 2021F 2022F 2023F 2024F 2025F 2030F 2035F 2040F
Operating cash 47 254 798 1 559 5 069 10 896 14 011 18 034 23 258 30 019 38 756 116 906 288 409 541 352
% Revenues 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2%
Amounts receivable 783 1 486 5 815 21 425 106 974 130 448 167 742 215 905 278 442 359 393 463 986 1 399 611 3 452 863 6 481 123
Collection period  121  43  53  100  173  98  98  98  98  98  98  98  98  98 
Biological assets 2 028 5 321 14 725 16 348 78 975 676 860 1 407 235 2 300 315 3 394 487 4 736 152 6 381 674 20 475 170 49 241 378 97 023 826
Changes in fair value 3 293 9 404 1 623 62 627 597 885 730 376 893 079 1 094 173 1 341 665 1 645 522 3 840 818 7 331 855 11 799 282
Inventory 4 355 22 153 45 981 101 607 262 105 307 909 357 335 415 090 483 128 562 787 655 733 1 207 274 1 518 920 1 453 995
Holding Period 196 249 334 343 314 314 298 283 269 256 243 198 153 118
Prepaid expenses and other assets 764 489 4 285 19 837 107 123 82 178 110 956 149 955 203 060 275 199 373 055 1 395 186 3 800 187 7 875 475
% Operating expenses 7% 2% 8% 13% 16% 17% 18% 19% 20% 21% 22% 27% 30% 33%
% Growth 5% 5% 5% 5% 5% 5% 2% 2% 2%
Accounts payable and accrued liabilities (4 278) (6 107) (15 386) (89 571) (226 533) (94 647) (121 706) (156 650) (202 024) (260 758) (336 646) (1 015 490) (2 505 231) (4 702 390)
Payable period  142  104  106  220  124  71  71  71  71  71  71  71  71  71 
Deferred revenue (533) (588) (900) 8 303 10 677 9 730 11 997 15 486 23 992 67 650 164 691 308 537
% Revenues 4% 1% 1% 2% 2% 1% 1% 1% 1% 1% 1% 1%
Property, plant and equipment 18 360 44 984 96 270 303 682 1 096 340 619 475 807 697 1 054 208 1 377 362 1 801 371 2 356 856 7 707 311 22 936 749 46 133 996
PP&E per square-foot 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79
Square-feet required 1 390 000 785 404 1 024 042 1 336 583 1 746 295 2 283 877 2 988 151 9 771 752 29 080 469 58 491 211
Kgs produced 24 320 47 353 61 741 80 585 105 287 137 699 180 161 589 155 1 753 310 3 526 533
Other long-term assets 8 340 25 902 12 429 15 982 20 571 26 530 34 243 44 208 133 354 328 987 617 517
% PP&E 2.75% 2.36% 2.55% 2.55% 2.55% 2.55% 2.55% 2.55% 2.55% 2.55% 2.55%
Goodwill 20 866 241 371 314 923 1 544 055 1 544 055 1 544 055 1 544 055 1 544 055 1 544 055 1 544 055 1 544 055 1 544 055 1 544 055
Intangible assets 38 31 861 162 263 101 526 519 556 1 172 731 1 583 409 2 139 943 2 621 791 3 214 818 3 942 901 9 203 139 16 643 514 18 447 117
% Revenues 407% 130% 230% 241% 253% 266% 252% 240% 228% 176% 129% 76%
% Change 5% 5% 5% -5% -5% -5% -5% -10% -10%
Deferred tax liability - Core (7 413) (32 740) (14 453) (85 364) (989 965) (1 966 190) (3 153 488) (4 582 803) (6 371 769) (8 737 101) (28 025 659) (67 400 735) (130 281 342)
PP&E (1 097) (1 126) 1 071 (10 876) (6 578) (8 577) (11 195) (14 626) (19 129) (25 028) (81 844) (243 567) (489 900)
% PP&E 2.44% 1.17% -0.35% 0.99% 1.06% 1.06% 1.06% 1.06% 1.06% 1.06% 1.06% 1.06% 1.06%
Intangibles (8 436) (42 703) (25 428) (78 163) (272 322) (367 686) (496 920) (608 810) (746 518) (915 588) (2 137 076) (3 864 818) (4 283 635)
% Intangibles 26% 26% 25% 15% 23% 23% 23% 23% 23% 23% 23% 23% 23%
Biological assets (7 201) (20 615) (29 780) (39 850) (859 533) (1 787 026) (2 921 133) (4 310 605) (6 014 365) (8 103 987) (26 001 094) (62 530 846) (123 209 020)
% Biological assets 135% 140% 182% 50% 127% 127% 127% 127% 127% 127% 127% 127% 127%
Loss carryforwards 9 100 30 494 35 157 42 867 146 814 195 445 274 106 349 585 406 589 305 847 192 701 (763 158) (2 300 440)
% EBIT 308% 200% 34% 8% 21% 21% 21% 21% 21% 21% 21% 21% 21%
Other 221 1 210 4 527 658 1 654 1 654 1 654 1 654 1 654 1 654 1 654 1 654 1 654
Other long-term liabilities - Core (171) (1 501) (137 760)
Invested Capital Core Business 21 926 111 860 522 794 784 323 3 296 442 3 480 671 3 931 203 4 557 669 5 179 281 5 940 996 6 751 469 14 208 506 30 013 788 45 443 262
Non-Core 2015A 2016A 2017A 2018A 2019A 2020F 2021F 2022F 2023F 2024F 2025F 2030F 2035F 2040F
Assets classified as held for sale 6 180
Investments in associates 63 106 112 385 101 147 91 032 81 929 73 736 66 362 63 044 51 350 65 537 83 643
78% -10% -10% -10% -10% -10% -5% 5% 5%
Marketable securities 2 034 133
Deferred tax liability - Non-Core (3 184) (21 866) (10 667) (22 324) (20 091) (18 082) (16 274) (14 647) (13 914) (11 333) (14 464) (18 461)
Investments (3 184) (21 866) (10 667) (22 324) (20 091) (18 082) (16 274) (14 647) (13 914) (11 333) (14 464) (18 461)
% Investments in associates 35% 9% 22% 22% 22% 22% 22% 22% 22% 22% 22%
Other long-term liabilities - Non-Core (50 058) (50 058) (50 058) (50 058) (50 058) (21 447)
Settlement liability (28 611) (28 611) (28 611) (28 611) (28 611)
Due to former shareholders of S&B (21 447) (21 447) (21 447) (21 447) (21 447) (21 447)
Invested Capital Non-Core Business 2 996 41 240 2 085 793 28 765 20 883 13 789 7 404 30 269 49 130 40 017 51 072 65 183
Financial Assets 2015A 2016A 2017A 2018A 2019A 2020F 2021F 2022F 2023F 2024F 2025F 2030F 2035F 2040F
Excess cash 21 399 15 143 101 002 321 001 2 475 761 4 794 399 5 492 699 5 709 852 5 655 083 5 216 397 5 113 447 14 399 990
Deferred tax liability - Financial 2 783
Other long-term liabilities - Financial (766) (61 150) (34 000) (8 445) (11 144) (14 706) (19 406) (25 608) (33 792)
Put liabilities (61 150) (6 400) (8 445) (11 144) (14 706) (19 406) (25 608) (33 792)
Other financial assets 804 24 030 163 463 363 427 363 427 363 427 363 427 363 427 363 427 363 427 363 427 363 427 363 427
Current portion of long-term debt (247) (553) (1 691) (1 557) (103 716) (103 716) (103 716) (103 716) (103 716) (103 716) (103 716) (103 716) (103 716) (103 716)
Financial debt (1 669) (3 469) (8 639) (6 865) (842 259) (687 122) (4 338 760)
Net Financial Assets 19 483 11 925 113 936 417 675 1 859 213 5 045 664 5 741 265 5 954 857 5 895 388 5 450 500 5 339 366 (427 411) (4 079 049) 14 659 701
Equity 2015A 2016A 2017A 2018A 2019A 2020F 2021F 2022F 2023F 2024F 2025F 2030F 2035F 2040F
Equity and Equity Equivalents 41 409 123 785 639 726 1 243 238 7 241 448 8 555 101 9 693 351 10 526 315 11 082 073 11 421 765 12 139 965 13 821 112 25 985 812 60 168 146
Transactions with Shareholders 85 872 507 415 623 545 6 682 068 1 974 725 1 974 725 1 974 725 1 974 725 1 974 725 1 974 725 1 974 725 1 974 725 1 974 725
CANOPY GROWTH CORPORATION
FORECASTING  REFORMULATED CASH FLOW STATEMENT
Fiscal Year Ending March 31
(Expressed in CDN $000's)
Core 2015A 2016A 2017A 2018A 2019A 2020F 2021F 2022F 2023F 2024F 2025F 2030F 2035F 2040F
NOPLAT (9 384) (3 190) (11 050) (91 473) (523 701) (706 618) (918 677) (1 224 363) (1 501 925) (1 718 315) (1 339 952) (1 058 431) 2 093 755 7 120 519
Depreciation and amortization 646 2 256 6 064 12 889 21 510 47 689 63 625 84 994 106 414 133 476 167 631 449 972 1 053 196 1 718 446
Operational Cash Flow (8 738) (934) (4 986) (78 584) (502 191) (658 929) (855 052) (1 139 369) (1 395 512) (1 584 838) (1 172 321) (608 458) 3 146 951 8 838 965
Invested Capital - Fixed Assets 18 398 97 711 499 904 728 471 3 185 853 3 348 689 3 951 143 4 758 777 5 569 738 6 594 487 7 888 021 18 587 859 41 453 305 66 742 685
Net CAPEX (81 569) (408 257) (241 456) (2 478 892) (210 525) (666 079) (892 628) (917 374) (1 158 225) (1 461 165) (3 507 925) (6 823 837) (8 186 541)
Invested Capital - NWC and Others 3 528 14 149 22 890 55 852 110 589 131 982 (19 939) (201 109) (390 456) (653 490) (1 136 552) (4 379 353) (11 439 517) (21 299 423)
Investment in NWC and Others (10 621) (8 741) (32 962) (54 737) (21 394) 151 922 181 169 189 348 263 034 483 061 1 119 278 1 646 747 2 356 012
Investment Cash Flow (92 190) (416 998) (274 418) (2 533 629) (231 919) (514 157) (711 459) (728 027) (895 191) (978 104) (2 388 648) (5 177 091) (5 830 530)
Free Cash Flow - Core Business (93 124) (421 984) (353 002) (3 035 820) (890 848) (1 369 209) (1 850 828) (2 123 538) (2 480 029) (2 150 425) (2 997 106) (2 030 139) 3 008 436
Non-Core 2015A 2016A 2017A 2018A 2019A 2020F 2021F 2022F 2023F 2024F 2025F 2030F 2035F 2040F
Operational Cash Flow (203) 15 863 32 608 (30 896) (4 424) (3 981) (3 583) (3 225) (2 902) (2 757) (2 246) (2 866) (3 658)
Invested Capital 2 996 41 240 2 085 793 28 765 20 883 13 789 7 404 30 269 49 130 40 017 51 072 65 183
Investment Cash Flow (2 996) (38 244) (2 044 553) 2 057 028 7 882 7 094 6 385 (22 865) (18 861) (2 432) (3 104)
Free Cash Flow - Non-Core Business (203) 12 867 (5 636) (2 075 449) 2 052 604 3 901 3 511 3 160 (25 767) (21 619) (2 246) (5 298) (6 762)
Free Cash Flow - Total (93 327) (409 117) (358 638) (5 111 270) 1 161 757 (1 365 308) (1 847 317) (2 120 378) (2 505 797) (2 172 044) (2 999 352) (2 035 438) 3 001 674
Financial 2015A 2016A 2017A 2018A 2019A 2020F 2021F 2022F 2023F 2024F 2025F 2030F 2035F 2040F
Financial Result 37 (103) 3 712 38 832 (129 260) 49 969 86 184 86 184 86 184 86 184 86 184 86 184 (93 731) 86 184
Net Financial Assets 19 483 11 925 113 936 417 675 1 859 213 5 045 664 5 741 265 5 954 857 5 895 388 5 450 500 5 339 366 (427 411) (4 079 049) 14 659 701
Investment in Net Financial Assets 7 558 (102 011) (303 739) (1 441 538) (3 186 451) (695 601) (213 592) 59 469 444 888 111 134 938 443 154 444 (5 062 583)
Net Cash Transactions with Shareholders 46 922 85 872 507 415 623 545 6 682 068 1 974 725 1 974 725 1 974 725 1 974 725 1 974 725 1 974 725 1 974 725 1 974 725 1 974 725
Financing Cash Flow 93 327 409 117 358 638 5 111 270 (1 161 757) 1 365 308 1 847 317 2 120 378 2 505 797 2 172 044 2 999 352 2 035 438 (3 001 674)
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The following report will focus on the emergence of a new market: CBD-infused edibles. New 
consumers’ needs and preferences are being created as they seek healthier, plant-based options 
for snacks and beverages and show willingness to try CBD-infused products. The exponential 
growth of this segment and its potential is generating deals between cannabis and beverage 
companies, who seek to take advantage of it.  The current concerns of this market are the high 
regulation involved and the uncertainty towards the future legalization of adult-use marijuana 
in most countries. Nevertheless, Canopy Growth is already investing millions in hemp 
















This work used infrastructure and resources funded by Fundação para a Ciência e a Tecnologia 
(UID/ECO/00124/2013, UID/ECO/00124/2019 and Social Sciences DataLab, Project 22209), 
POR Lisboa (LISBOA-01-0145-FEDER-007722 and Social Sciences DataLab, Project 22209) 
and POR Norte (Social Sciences DataLab, Project 22209). 
CBD-Infused Edibles: Market Size and Potential 
Upon the legalization of recreational marijuana in Canada, the market for edibles and beverages 
infused with cannabis components has been evolving at a fast pace. The North American market 
size for CBD-infused edibles is estimated to reach $4.1 billion by 2022 ( CAGR of 33%)1. 
Cogent Infotech conducted a study using social listening techniques, such as monitoring digital 
conversations of individuals to track their mentions of CBD-infused products. It revealed an 
exponential increase in the number of times CBD edibles are mentioned in conversations. As a 
matter of fact, over the last three years, they have been quoted approximately 158 thousand 
times. Exhibit 1 illustrates the most desired CBD products measured by how many times they 
were mentioned by individuals. It shows that most people are interested in trying CBD-infused 
drinks as they were cited over 23 thousand times.  
An additional important insight from this study regards the potential consumers of the market. 
Even though 54% of digital conversations were initiated by males, 46% of women were equally 
engaged in the conversation. In what comes to the consumers’ age span, 9% were underage, 
12% were placed between 18 and 24 years old, 31% within 25 and 44 years old, 35% were 
between 45 and 64 years old and the remaining 12% were over 64 years old2.  
Taking only the US and Canadian markets into consideration, which have the largest potential 
for legal CBD-edibles at the moment, and according to the previously mentioned numbers, an 
estimation on the current potential market for the CBD-infused edibles was performed (exhibit 
2). Considering population per age group of Canada and the US and current marijuana 
consumption per age group, it is possible to obtain the current number of marijuana consumers, 
which totals 42.11 million in the US and 7.76 million in Canada. When applying the previously 
mentioned percentages of prospect consumers for CBD-infused edibles into these values 
obtained, I get a total of 7.36 million potential consumers in the US and 1.41 million in Canada. 
 
1 PRNewswire. 2019. “Strong Demand for CBD Edibles to Create a $4.1 Billion Market by 2022”. Accessed December 2019. 
https://www.prnewswire.com/news-releases/strong-demand-for-cbd-edibles-to-create-a-4-1-billion-market-by-2022--300890266.html 
2 Cogent Infotech. 2019. “Insights Into the $22 billion CBD Edibles”. Accessed December 2019. https://cogentinfo.com/resources/social-listening-analytics/cbd-industry-insights.pdf 
Cannabis Companies’ Interest and Investment in the Industry 
The increasing potential of this market is appealing to cannabis’ companies, which has been 
incentivizing and leading them to invest millions in the development of CBD-infused products. 
For instance, Tilray has already announced a partnership with the World’s largest brewer, 
Anheuser-Busch InBev, where each invested $50 million to jointly research and produce 
cannabis-infused non-alcoholic beverages, one of the most consumer-demanded products3.  
Moreover, HEXO Corp. and Molson Coors created a joint venture, Truss Beverage Co., which 
will be launching six CBD-infused beverages in Canada. The first, Flow Glow, a natural spring 
water containing 10mg of CBD, was planned to be launched in December 20194. 
Impact on the Alcoholic and Non-Alcoholic Beverages Market 
Consumers are progressively disregarding the consumption of sugar-filled drinks in favor of 
healthier alternatives, such as water, which surpassed soda consumption for the first time in 
20165. These recent trends for healthier, plant-based alternatives to sodas and alcoholic 
beverages, combined with the legalization of marijuana, are driving consumers away from the 
beverages market. In fact, beer companies have been facing a 5-year decline in the US beer 
consumption, which has been creating interest from these companies in the CBD market. 
Among them there is a giant in the industry, Diageo, which owns the Guinness brand. It is 
currently in talks with several and different Canadian marijuana companies in order to develop 
cannabis-based beverages. Phivida Holdings Inc. is also taking advantage of the market through 
the launch of its Oki brand of active-hemp, CBD-infused waters and iced teas. The company is 
targeting health-concerned consumers, looking for new products to improve their well-being6. 
 
3 Beverage Daily. 2019. “AB InBev to Launch Its CBD-Infused Beverages in Canada in December”. Accessed December 2019. 
https://www.beveragedaily.com/Article/2019/10/11/AB-InBev-CBD-infused-beverages-to-launch-in-Canada-in-December 
4 Beverage Daily. 2019. “Molson Coord to Launch Six Cannabis Beverage Brands in Canada: Starting with Flow Glow”. Accessed December 2019. 
https://www.beveragedaily.com/Article/2019/10/17/Molson-Coors-and-Truss-to-launch-6-cannabis-beverages-in-Canada  
5 Fortune. 2017. “Americans Are Now Drinking More Bottled Water Than Soda”. Accessed December 2019. https://fortune.com/2017/03/10/soda-tax-bottled-
water-americans/ 
6 PR Newswire. 2019. “CBD Beverages—Possible Next Big Disruptor in the Drinks Industry”. Accessed December 2019. https://www.prnewswire.com/news-
releases/cbd-beveragespossible-next-big-disruptor-in-the-drinks-industry-300815422.html 
Despite the thrill over the CBD-infused drinks market and the large investments that big 
beverage companies are doing, they still hold some concerns associated with this new market. 
Companies are evaluating whether these varieties of drinks will be well-received by consumers 
or if it they will harm their reputation. One of the reasons why such might occur is due to the 
lack of public knowledge on the matter. People are generally not familiar with the concept of 
CBD and potentially unaware if it is even safe or legal. 
People’s Interest in the Industry 
Given the companies’ uncertainty on consumers’ behaviours towards change, it is important to 
assess their potential reactions. In that sense, A.T. Kearney ran a study on the perception of 
consumers regarding non-psychoactive cannabis (CBD-related), The Cannabis Opportunity7. 
The study revealed that if a well-known beverage company were to become involved in the 
industry, 60% of the respondents would maintain a neutral position on their perception of the 
organization. In the case of non-alcoholic beverage companies, 25% would improve their 
perception. The same goes for alcoholic ones. While 61% of the respondents would not change 
their perception of a company if it entered the cannabis-infused beverages market, 21% would 
perceive it as an improvement. Furthermore, most of the people surveyed are willing to try a 
legal therapeutic product infused with Cannabis (78% in the US and 75% in Canada). Hence, 
and in accordance with the new consumer trend for “health-consciousness”, alcohol and soda 
companies intend to take advantage of the CBD-market and fill the gap in customer preferences.  
Legalization 
Following the market potential and the interest of companies, it is now of the upmost 
importance to assess the progress and recent developments in the legalization process of CBD-
infused edibles. In the United States, even though the legalization of cannabis-infused products 
is still a sensitive topic, it is expected to take place soon. Such would imply the removal of 
 
7 AT Kearney. 2019. “The Cannabis Opportunity”. Accessed December 2019. 
https://www.atkearney.com/documents/20152/1555409/The+Cannabis+Opportunity.pdf/bf18db64-c9b9-eb10-013c-4f4c250525a6?t=1539899590994 
hemp from the Controlled Substances Act, meaning that it would no longer be an illegal 
substance. Nonetheless, cannabis-derived products would still be regulated by the FDA (Food 
and Drug Administration) under the Federal Food, Drug and Cosmetic Act. Some states, such 
as California, have already allowed the sale of CBD-infused edibles and beverages in licensed 
dispensaries, although these permissions violate FDA regulations.  
In Canada, cannabis-infused edibles and beverages became legal on October 17, 2019, exactly 
one year after the legalization of recreational marijuana in dry forms (“joints”). That being said, 
the circulation of these edibles in the appropriate selling points can take from 60 to 90 days, as 
Health Canada must inspect and approve the products prior to sale8. One constraint in this 
matter is that the products cannot be appealing to children, i.e. companies are not allowed to 
produce gummy worms infused with cannabis.  
Briefly addressing Europe, it is more difficult to predict when and if the EU will legalize these 
products, since the legalization process of medical marijuana is still slow and controversial. 
Only Germany, Czech Republic, Italy, and Malta have yet legalized medical marijuana. The 
UK is on its way to doing the same. Therefore, recreational marijuana and edibles are even 
further from becoming legal. 
Canopy Growth Involvement in the CBD market 
As previously mentioned, cannabis companies are taking advantage of the market and investing 
vigorously in the development of CBD-infused edibles. Canopy Growth does not fall behind. 
Constellation Brands has invested over C$5 billion in Canopy Growth, acquiring 38% of the 
company. From the moment of the investment, there have already been some developments of 
CBD-infused products by the company. Canopy has been preparing its entrance in the cannabis 
edibles market one year prior to its legalization, by partnering with Hummingbird, a well-
 
8 Leader Post. 2019. “Cannabis Edibles Now Legal in Canada, But Won’t Be Available for 60 Days”. Accessed December 2019. 
https://leaderpost.com/news/saskatchewan/legal-but-unavailable-what-you-need-to-know-about-cannabis-edibles 
known chocolate brand, to produce a jointly made product9. Furthermore, Canapar, a 49% 
subsidiary of Canopy Rivers (the venture capital firm of Canopy Growth) is currently building 
the largest facility to extract CBD in Ragusa, Sicily10. By focusing on the extraction of CBD 
from what was once hemp waste, production is expected to be 10 times more profitable for 
local farmers than growing other produces, like cereal. 
Even though the industry is still emerging, as these products are only legal since October 2019 
and exclusively in Canada, it is possible to see in exhibit 3 that the 3-year rolling-beta of Canopy 
Growth is decreasing in the last semester of 2019 (from almost 1.3 to 1). While the beta is still 
similar to that of the pharmaceutical industry (0.98), there is a clear declining tendency in the 
last months, which can indicate the beta is reaching values closer to that of the beverages and 
food industries (0.79 and 0.78, respectively)11. Hence, there is the possibility that CBD-infused 











Exhibit 2: Estimated consumers for the CBD-edibles market in the US and Canada 
 
9 Ottawa Citizen. 2018. “Eyeing Legal Edibles, Weed Giant Teams Up With Almonte Chocolate-Maker Hummingbird”. https://ottawacitizen.com/business/local-
business/eyeing-legal-edibles-weed-giant-teams-up-with-almonte-chocolate-maker-hummingbird  
10 Forbes. 2019. “How the Cannabis Industry Is Revolutionizing the Beverage Sector”. Accessed December 2019. 
https://www.forbes.com/sites/joemicallef/2019/05/22/how-the-cannabis-industry-is-revolutionizing-the-beverage-sector/#3773bfe65673 
11 Data on Betas taken from Bloomberg on January 3rd, 2019 
Age groups Population
(in millions)
Marijuana consumption Marijuana consumers
(in millions)
CBD-edibles consumption Potential CBD-consumers
(in millions)
15 - 24 42.96 27% 11.60 21% 2.44
25 - 34 45.69 30% 13.62 16% 2.18
35 - 44 41.28 21% 8.46 15% 1.27
45 - 54 41.63 11% 4.41 16% 0.71
55 - 64 42.27 10% 4.02 19% 0.76
65+ 52.42 8% 3.98 12% 0.48
18 - 29 5.11 24% 1.23 20% 0.25
30 - 49 10 13% 1.30 31% 0.40
50 - 64 7.76 11% 0.85 27% 0.23
65+ 6.6 6% 0.40 12% 0.05













Source: Canopy Growth Equity Research project 
